🟠 Conclusions: Workforce reductions and halted programs reflect gene editing firms’ focus on preserving cash amid commercialization challenges, signaling potential volatility ahead for the sector. #CRISPR #biotech $VRTX $NTLA $PRME $EDIT @FDA